Silo Pharma (NASDAQ:SILO) and Harrow (NASDAQ:HROW) Critical Survey

Harrow (NASDAQ:HROW – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

Risk and Volatility

Harrow has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Harrow and Silo Pharma, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harrow 2 1 6 0 2.44
Silo Pharma 1 0 0 0 1.00

Harrow currently has a consensus price target of $66.20, suggesting a potential upside of 127.57%. Given Harrow’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Harrow is more favorable than Silo Pharma.

Profitability

This table compares Harrow and Silo Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harrow -9.39% -69.81% -5.16%
Silo Pharma -6,726.39% -66.16% -54.26%

Insider and Institutional Ownership

72.8% of Harrow shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 3.6% of Silo Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Harrow and Silo Pharma”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harrow $303.25 million 3.60 -$5.14 million ($0.78) -37.29
Silo Pharma $54,077.00 46.25 -$4.23 million ($2.77) -0.57

Silo Pharma has lower revenue, but higher earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Harrow beats Silo Pharma on 9 of the 14 factors compared between the two stocks.

About Harrow

(Get Free Report)

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.

About Silo Pharma

(Get Free Report)

Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on treatments for central nervous system disorders and pain conditions. Its research programs include potential therapies for post-traumatic stress disorder, Alzheimer’s disease and chronic pain. The company works on drug candidates and delivery approaches involving compounds such as ketamine, including formulations intended to support targeted or sustained treatment. Silo’s programs remain in development, and the company does not have a marketed product.

Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.